10q10k10q10k.net
MIMEDX GROUP, INC.

MIMEDX GROUP, INC.MDXGEarnings & Financial Report

Nasdaq

MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.

MDXG Q4 2025 Key Financial Metrics

売上高

$118.1M

粗利益

$99.0M

営業利益

$21.1M

純利益

$15.2M

粗利益率

83.9%

営業利益率

17.8%

純利益率

12.9%

前年比成長

27.1%

EPS

$0.10

資金フロー

MIMEDX GROUP, INC. Q4 2025 Financial Summary

MIMEDX GROUP, INC. reported revenue of $118.1M (up 27.1% YoY) for Q4 2025, with a net profit of $15.2M (up 104.2% YoY) (12.9% margin). Cost of goods sold was $19.1M, operating expenses totaled $78.0M.

Key Financial Metrics

Total Revenue$118.1M
Net Profit$15.2M
Gross Margin83.9%
Operating Margin17.8%
Report PeriodQ4 2025

Revenue Breakdown

MIMEDX GROUP, INC. Q4 2025 revenue of $118.1M breaks down across 2 segments, led by Wound at $78.7M (66.6% of total).

SegmentRevenue% of Total
Wound$78.7M66.6%
Surgical$39.4M33.4%

MIMEDX GROUP, INC. Revenue by Segment — Quarterly Trend

MIMEDX GROUP, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Wound and Surgical) has evolved quarter over quarter.

SegmentQ4 2025Q3 2025Q2 2025Q1 2025
Wound$78.7M$77.1M$64.5M$56.1M
Surgical$39.4M$36.6M$34.1M$32.1M

MIMEDX GROUP, INC. Annual Revenue by Year

MIMEDX GROUP, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $418.6M). Click any linked year to see what changed vs the prior 10-K.

YearAnnual Revenue
2025$418.6Mvs 2024
2024$348.9Mvs 2023
2023$321.5Mvs 2022
2022$267.8M

MIMEDX GROUP, INC. Quarterly Revenue & Net Profit History

MIMEDX GROUP, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 2025$118.1M+27.1%$15.2M12.9%
Q3 2025$113.7M+35.3%$16.7M14.7%
Q2 2025$98.6M+13.1%$9.6M9.8%
Q1 2025$88.2M+4.1%$7.0M8.0%
Q4 2024$92.9M+7.0%$7.4M8.0%
Q3 2024$84.1M+2.9%$8.1M9.6%
Q2 2024$87.2M+7.3%$17.6M20.2%
Q1 2024$84.7M+18.2%$9.3M10.9%

損益計算書

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
売上高$84.7M$87.2M$84.1M$92.9M$88.2M$98.6M$113.7M$118.1M
前年比成長18.2%7.3%2.9%7.0%4.1%13.1%35.3%27.1%

貸借対照表

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
総資産$221.7M$230.2M$243.9M$263.9M$270.4M$291.1M$319.0M$342.7M
総負債$66.0M$62.1M$62.9M$70.8M$67.6M$74.5M$80.0M$86.1M
株主資本$155.7M$168.0M$181.0M$193.1M$202.8M$216.6M$238.9M$256.5M

キャッシュフロー

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
営業CF$6.0M$21.8M$19.6M$18.8M$5.3M$14.4M$29.3M$25.0M